Medicaid
Covered with requirementsWhat you need to qualify
- Diagnosis documented with a code
- Trial of metformin for at least 730 days, or a documented reason it can't be used
- Prior trial of 3 other GLP-1 medications (preferred GLP-1 receptor agonists (Ozempic, Trulicity, Victoza)) for at least 90 days
Qualification pathways
You can qualify through any one of these.
Non-preferred agent — documented compliance to current therapy
All of:
- Mounjaro is a non-preferred agent
- Documented compliance to current therapy
Non-preferred agent — step therapy failure of preferred agents
All of:
- Mounjaro is a non-preferred agent
- Documented diagnosis of type 2 diabetes mellitus in the past year
- Adequate therapeutic trial of metformin in the past 2 years
- Failure to achieve desired therapeutic outcomes with trial on 3 or more preferred agents for 3 months each
- Clinical consultant review for reason of medical necessity why Zepbound cannot be utilized
Plus any one of:
- Documented trial period of preferred agents
- Documented ADE/ADR to preferred agents
Documentation to bring
- Documented diagnosis of type 2 diabetes mellitus in the past year
- Documentation of adequate therapeutic trial of metformin in the past 2 years
- Documentation of trial on 3 or more preferred GLP-1 agents for 3 months each with failure to achieve desired therapeutic outcomes, OR documented ADE/ADR to preferred agents
- Clinical consultant review documentation for reason of medical necessity why Zepbound cannot be utilized
- OR: Documentation of compliance to current therapy (alternative pathway)
Quantity limits
- 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, 15 mg/0.5 mL — 2 mL per 28 days
Approval and renewal
- Initial approval: 12 months
- Renewal: every 12 months
Not covered when
- Concurrent therapy with another GLP-1 receptor agonist
Policy note: Mounjaro is a non-preferred agent on the MO HealthNet PDL for diabetes. In addition to standard non-preferred agent step therapy criteria, there is an additional requirement for clinical consultant review for medical necessity documenting why Zepbound cannot be utilized. The document notes GLP-1 receptor agonists for anti-obesity are covered under a separate PDL edit; Zepbound is referenced as a comparator/alternative rather than being covered under this policy.
Policy effective January 9, 2025 · verified June 3, 2026 · source: policy-310.html